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 2 
Abstract 22 
There is established evidence that cytotoxic CD8+ T cells are important mediators of 23 
immunity against the bovine intracellular protozoan parasite T. parva. However, the 24 
mechanism by which the specific CD8+ T cells kill parasitized cells is not 25 
understood. Although the predominant pathway used by human and murine CD8+ T 26 
cells to kill pathogen-infected cells is granule exocytosis, involving release of perforin 27 
and granzyme B, there is to date a lack of published information on the biological 28 
activities of bovine granzyme B. The present study set out to define the functional 29 
activities of bovine granzyme B and determine its role in mediating killing of T. parva-30 
parasitized cells. DNA constructs encoding functional and non-functional forms of 31 
bovine granzyme B were produced and the proteins expressed in Cos-7 cells were 32 
used to establish an enzymatic assay to detect and quantify expression of functional 33 
granzyme B protein. Using this assay, the levels of killing of different T. parva-34 
specific CD8+ T cell clones were found to be significantly correlated with levels of 35 
granzyme B protein, but not mRNA transcript, expression. Experiments using 36 
inhibitors specific for perforin and granzyme B confirmed that CD8+ T cell killing of 37 
parasitized cells is dependent on granule exocytosis and specifically granzyme B. 38 
Further studies showed that granzyme B-mediated death of parasitized cells is 39 
independent of caspases and that granzyme B activates the pro-apoptotic molecule 40 
Bid.   41 
 42 
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 3 
 46 
Introduction  47 
Antigen-specific CD8+ T cell responses have been shown to play a key role in 48 
immunity to a number of viral, bacterial and parasitic infections. One such parasite is 49 
the tick-borne protozoan Theileria parva. T. parva infects and transforms bovine 50 
lymphocytes resulting in an acute, often fatal, lymphoproliferative disease, which is a 51 
major constraint to cattle production in a large part of eastern and southern Africa 52 
(1). Following invasion of host lymphocytes, the parasite enters the cytosol where it 53 
develops to the schizont stage, which triggers a number to signalling pathways that 54 
promote host cell proliferation and inhibit apoptosis. By associating with the mitotic 55 
spindle of the activated lymphocyte, the parasite is able to divide at the same time as 56 
the host cell, ensuring that infection is retained in both daughter cells. Hence, the 57 
parasite remains in an intracellular location during this stage of development. Cattle 58 
that recover from infection with T. parva are solidly immune to subsequent challenge 59 
with the same parasite strain but show variable susceptibility to other parasite strains 60 
(2). Development of immunity is associated with a potent parasite-specific CD8+ T 61 
cell response directed against the parasitized lymphoblasts (3, 4), and transfer of 62 
purified CD8+ T cells from immune to naïve twin calves has been shown to confer 63 
immunity to parasite challenge (5). The mechanism by which CD8+ T cells mediate 64 
protection against T. parva is poorly understood. They exhibit strong MHC-restricted 65 
cytotoxic activity and secrete IFNγ and TNFα; however, unlike other intracellular 66 
protozoa (6, 7), these cytokines do not appear to have a direct effector role against 67 
the parasite (8). Hence, cytotoxicity is considered likely to have an important role in 68 
immunity, although direct evidence for this is lacking and at present there is no 69 
information on the molecular mediators of cell killing.  70 
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 4 
As an initial step towards investigating development of subunit vaccines, T. parva-71 
specific CD8+ T cell lines have been used successfully to identify a number of target 72 
antigens, employing high-throughput screens of expressed parasite cDNAs. 73 
Although prime-boost immunisation of cattle with recombinant poxviruses expressing 74 
some of these antigens was found to generate specific CD8+ T cell responses, the 75 
immunised animals exhibited only partial protection against parasite challenge. A 76 
striking feature of the CD8+ T cells induced by this immunisation protocol is that they 77 
showed poor cytotoxic activity compared to CD8+ T cells generated by immunisation 78 
with live parasites, suggesting poor functional differentiation of the T cell response 79 
(9). As with similar results derived from other vaccine trials, these findings highlight a 80 
paucity of knowledge of the molecular mechanisms that determine the effector 81 
function of vaccine-induced CD8+ T-cells. Understanding the mechanisms of killing 82 
of T. parva-infected cells by bovine CD8 T cells is required to identify relevant 83 
molecular markers that can be used to monitor vaccine-induced immune responses 84 
and accelerate vaccine development. 85 
Killing of target cells by CD8+ T cells is achieved by release of the contents of 86 
secretory lysosomes, known as lytic granules, at the immunological synapse formed 87 
upon recognition of class I MHC-bound antigenic peptides by the T cell receptor. Cell 88 
killing is initiated by perforin, which creates transient pores in the membrane of the 89 
target cell, facilitating uptake into the cytosol of a family of serine proteases known 90 
as granzymes. Granzymes exhibit different primary substrate specificities and are 91 
able to act on various cellular protein substrates to trigger programmed cell death 92 
(10). Five granzymes (A, B, K, H and M) have been identified in humans; mice 93 
express four of these granzymes (A, B, K and M) and 6 additional granzymes (C, E, 94 
D, F, G and N) (11). We have recently shown that cattle express the same 5 95 
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 5 
granzymes described in humans, plus a novel granzyme (designated granzyme O) 96 
(12). Granzymes have been classified into three distinct evolutionary groups, based 97 
on their primary substrate specificities, namely trypsin-like (granzymes A and K), 98 
chymotrypsin-like (granzymes B, H, C, E, M, D, F, G and N) and metase-like 99 
(granzyme M) (13). The most extensively studied of these proteases, granzyme B, 100 
cleaves aspartic acid residues. In vitro studies have demonstrated that granzyme B 101 
induces target cell death by two main pathways, one involving direct proteolytic 102 
activation of caspases (leading to DNA damage) and the other by triggering outer 103 
mitochondrial membrane permeabilisation via cleavage of the pro-apoptotic protein, 104 
BH3-interaction domain death agonist (Bid) (14). The relative physiological roles of 105 
these activities in vivo remain unclear, particularly in view of the potential functional 106 
redundancy among the granzymes. Nevertheless, gene knockout mice deficient in 107 
granzyme B have been shown to have reduced levels of CD8+ T cell-mediated 108 
cytotoxicity and have increased susceptibility to some viral infections. Despite the 109 
residual ability of CD8+ T cells from granzyme B-/- mice to kill target cells, they were 110 
unable to induce DNA fragmentation (15). Extrapolation of findings in mice to other 111 
mammalian species is also complicated by the finding of differences in protein 112 
substrate specificity between murine and human granzyme B; in contrast to human 113 
granzyme B, mouse granzyme B is inefficient at cleaving Bid and is therefore 114 
believed to rely largely on direct activation of caspases (16).  115 
In view of the potential importance of CD8+ T cell mediated cytotoxicity as an 116 
effector mechanism against T. parva, the current study set out to examine the 117 
biological activity of bovine granzyme B and to investigate its role in CD8+ T cell-118 
mediated killing of T. parva-infected cells. The results demonstrate that granzmye B 119 
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 6 
plays a key role in killing of parasitized cells, that it is able to cleave Bid and that 120 
killing occurs predominantly by a caspase-independent pathway.  121 
 122 
Results 123 
Establishing an in vitro assay of granzyme B activity. In order to assess the role 124 
of granzyme B in killing of T. parva-infected cells, it was necessary to develop 125 
methods for measuring its biological activity. Bovine granzyme B expressed in Cos-7 126 
cells using the pFLAG eukaryotic expression vector (Figure 1A) was tested for 127 
enzymatic activity using a substrate assay employing AC-IEPD-pNA, which contains 128 
a tetrapeptide recognized specifically by human and murine granzyme B.  As shown 129 
in Figure 1B, the active form of Granzyme B (pFLAG-Function - with the pro-130 
dipeptide removed) displayed strong activity against the substrate, whereas the 131 
native form (pFLAG-WT) and a version containing a mutation in the active tri-peptide 132 
site (pFLAG-Mutant) were inactive. As a substrate-specific control, the chymotrypsin 133 
substrate Suc-GGF-pNA was used in the assay and no signal was detected with any 134 
of the cattle granzyme B constructs. 135 
To confirm the specificity of the expressed granzyme B, the enzymatic activity was 136 
measured in the presence or absence of the granzyme B inhibitor AC-IEPD-CHO. 137 
The specific inhibitor dramatically reduced the activity of the cattle granzyme B 138 
preparation by about 4-fold, close to the background level (Figure 1C), indicating 139 
effective inhibitory capacity of AC-IEPD-CHO for cattle granzyme B.  140 
Relationship of cytotoxic activity and granzyme B transcript profiles. Analysis 141 
of cDNA from T. parva-specific CD8+ T cell lines by PCR employing primers that 142 
amplify transcripts for 6 defined bovine granzymes demonstrated expression of all 143 
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 7 
six genes, including granzyme B (Figure 2A). The kinetics of granzyme B mRNA 144 
expression were examined using a semi-quantitative PCR to determine whether 145 
expression was strongly influenced by the time interval after antigenic stimulation. 146 
Examination of cDNA prepared from CD8+ T cells at 2-3 day intervals, between 2 147 
and 14 days after stimulation with γ-irradiated T. parva-infected cells, demonstrated 148 
that near maximal levels of gene expression were achieved between 5 and 7 days 149 
after antigenic stimulation, with a subsequent decline in expression (Figure 2B and 150 
C). Cells harvested 6-7 days after antigenic stimulation were used for subsequent 151 
experiments. To determine whether the levels of killing by CD8+ T cells are related 152 
to granzyme B and perforin mRNA expression, CD8+ T cell clones exhibiting 153 
different levels of killing were analysed using a semi-quantitative PCR. Two sets of 154 
cloned CD8+ T cell lines derived from different animals (641 and 011) were 155 
examined; each set of lines expressed identical TCRβ chains and recognised the 156 
same epitope but exhibited different levels of cytotoxic activity (ranging from 0% to 157 
75%) on autologous parasitized cells (Figure 2D). Transcripts for granzyme B and 158 
perforin were detected in all 8 T cell clones (Figure 2E). Overall, there was no 159 
consistent pattern of either granzyme B (r= 0.438, p= 0.278) or perforin (r= -0.104, 160 
p= 0.806) mRNA transcript expression that correlated with killing activity (Figure 2F).  161 
Relationship of cytotoxic activity and level of granzyme B protein expression. 162 
A series of CD8+ T cell clones specific for the same epitope in the Tp1 T. parva 163 
antigen (Tp1214-224) were used to examine the relationship between killing activity 164 
and granzyme B protein expression. These CD8+ clones exhibited maximal levels of  165 
killing of infected target cells, ranging from 1% to 47%, at effector to target ratios of 166 
1:1 or greater (Supplementary 1). Assays of granzyme B were conducted at a 167 
standard effector to target ratio of 2:1 to ensure maximal killing activity (Figure 3A). 168 
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 8 
Granzyme B activity in culture supernatants and in cell lysates of these clones 169 
following incubation with infected cells was measured using the in vitro substrate-170 
specific assay established above. As shown in Figure 3A, the T cell clones showed 171 
variable levels of granzyme B release following exposure to antigen-expressing cells 172 
(which prior assays had confirmed do not express granzyme B protein, data not 173 
shown). The levels of granzyme activity in cell supernatants showed a highly 174 
significant correlation with the levels of granzyme protein in lysates of the respective 175 
clones (r= 0.953, p< 0.0001 – Figure 3B), indicating that the levels of enzyme 176 
release reflect the cell content rather than inherent differences in rates of release 177 
during degranulation. The levels of granzyme B content of the clones also showed a 178 
statistically significant correlation (r =0.732, p= 0.007) with the levels of cytotoxicity of 179 
the T cell clones (Figure 3C). 180 
Cytotoxic activity of T cells is dependent on perforin and granzyme B. The 181 
involvement of lytic granule exocytosis and specifically the role of granzyme B in cell 182 
killing by bovine CD8+ T cells were investigated by testing the effect of specific 183 
inhibitors of perforin and granzyme B.  Cytotoxicity assays were first conducted in 184 
the presence of a range of concentrations of concanamycin A (CMA), an inhibitor of 185 
vacuolar type H+-ATPase (17), which raises the pH of the lytic granule and thus 186 
induces degradation of perforin (18). The effect of CMA on cytotoxic activity was 187 
examined using an un-cloned CD8+ T cell line assayed either on T. parva-infected or 188 
peptide-pulsed target cells, and 3 cloned CD8+ T cell lines assayed on infected 189 
target cells. Concentrations of 10ng/ml or greater of CMA were found to completely 190 
ablate killing of all T cell lines but did not affect the viability of the target cells (Figure 191 
4A and B) or the CD8+ T cells (data not shown).  The results indicate that lysis of T. 192 
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 9 
parva-infected cells by CD8+ T cells is dependent on perforin, implying that killing is 193 
mediated by release of granule enzymes.  194 
To examine the role of granzyme B in cell killing, several specific inhibitors used in 195 
studies of murine and human CD8+ T cells were first tested for their ability to inhibit 196 
granzyme B activity in bovine CD8+ T cell lysates tested using the in vitro substrate-197 
specific assay. Although AC-IEPD-CHO was the most potent inhibitor, reducing 198 
granzyme B activity by approximately 80% (Supplementary 2), its lack of membrane-199 
permeability, prohibits its use in cellular assays. The membrane-permeable agent Z-200 
IETD-FMK, which inhibits killing by human CD8+ T cells (19, 20), inhibited bovine 201 
granzyme B activity by approximately 50% in the substrate assay (Supplementary 2), 202 
so was used in subsequent experiments. Pre-incubation of T. parva-specific CD8+ T 203 
cells with Z-IETD-FMK for one hour prior to use in a cytotoxicity assay resulted in 204 
complete inhibition of cytotoxic activity of all 3 cloned T cell lines tested (Figure 4C). 205 
A control compound Z-VAD-FMK (a caspase inhibitor that does not affect granzyme 206 
B activity of effector cells) did not affect cell killing. 207 
In conclusion, these findings reveal that Z-IETD-FMK specifically and effectively 208 
blocks the activity of cattle granzyme B and inhibits killing of target cells by bovine 209 
CD8+ T cells - indicating that granzyme B is an important mediator for killing of T. 210 
parva infected cells.  211 
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 10 
Cytotoxic activity of T cells is not dependent on caspases, but is associated 212 
with activation of Bid. To examine the role of caspases in cell killing, experiments 213 
were undertaken to test the ability of the pan-caspase inhibitor Z-VAD-FMK and its 214 
control Z-FA-FMK to block killing by two T. parva-specific CD8+ T cell clones. In 215 
contrast to previous experiments in which this inhibitor was pre-incubated with 216 
effector cells (as a negative control), these experiments involved pre-incubation with 217 
the target cells. Cytotoxic activity of the CD8+ T cell clones was blocked by inclusion 218 
of inhibitors of perforin and granzyme B (CMA and Z-IETD-FMK respectively) but 219 
was unaffected by pre-incubation with Z-VAD-FMK (Figure 5A),  demonstrating that 220 
the granzyme B-dependent killing by these clones was independent of caspase 221 
activity. In contrast, Z-VAD-FMK specifically blocked lysis of Theileria-infected cells 222 
induced by the pro-apoptotic agent cisplatin (Supplementary 3), which is known to 223 
mediate cytotoxicity through caspase induction. These results therefore indicate that 224 
granzyme B-mediated killing of Theileria-infected cells by specific CD8+ T cells is not 225 
dependent on caspases.  226 
The other known mechanism by which granzyme B induces cell death is through 227 
cleavage, and so activation, of the pro-apoptotic molecule Bid. To investigate this we 228 
sought to examine the ability of bovine granzyme B to cleave bovine Bid. Wild-type 229 
bovine Bid was expressed in E.coli BL21 with cDNA incorporated into the pET-15b 230 
expression vector, which carries an N-terminal His-Tag sequence. Purified 231 
recombinant bovine Bid protein (Figure 5B) was incubated for 2 hours with serially 232 
titrated concentrations of the active form of bovine granzyme B (confirmed using the 233 
specific substrate assay) and the reaction products were separated by SDS-PAGE 234 
(Figure 5C). Bovine recombinant Bid was cleaved by active bovine granzyme B as 235 
revealed by the detection of an N-terminus 11kDa fragment of bovine recombinant 236 
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 11 
Bid of the expected size (based on the predicted cleavage site) by an anti-His-Tag 237 
antibody in Western Blot (Figure 5D). A reduction in the concentration of bovine 238 
granzyme B was associated with a declining ability to cleave bovine recombinant 239 
Bid. Additional smaller bands of approximately 5kDa and 8kDa, present in the 240 
Commassie blue-stained gels but not detected in the Western blot, may represent 241 
additional smaller fragments of Bid. As controls, an inactive form of bovine granzyme 242 
B with a serine to alanine substitution at position 195, mock-transfected cells (pFLAG 243 
without an insert) and Cos-7 cells alone were analysed; none yielded truncated Bid 244 
products, indicating an inability to cleave bovine recombinant Bid. In conclusion, 245 
these results demonstrate that bovine granzyme B cleaves Bid, indicating that 246 
cytotoxicity may be mediated by activation of Bid. 247 
 248 
Discussion 249 
In this study we aimed to examine the role of bovine granzyme B in the cytotoxic 250 
function of T. parva-specific CD8+ T-cell responses. To achieve this, we established 251 
an in vitro substrate-specific assay to detect and quantify expression of bovine 252 
granzyme B protein, employing recombinant bovine granzyme B expressed in Cos-7 253 
cells. Using this assay, we showed that the levels of killing of different T. parva-254 
specific CD8+ T cell clones are significantly correlated with levels of granzyme B 255 
protein and that killing of infected cells by bovine CD8+ T cells is mediated by the 256 
granule exocytosis pathway and critically requires granzyme B for induction of cell 257 
death. Furthermore, we provided evidence that granzyme B-mediated death of 258 
parasitized cells is independent of caspases, suggesting that instead the cell death 259 
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 12 
may be induced via activation of Bid, which we show is cleaved by bovine granzyme 260 
B.  261 
Granzyme B was selected for analysis in this study as it has been shown to be the 262 
most potent effector molecule utilized by CD8+ T cells to kill infected cells in both 263 
humans and mice. Due to the lack of prior information on bovine granzyme B, 264 
studies of its biological activity were required to investigate its role in killing of T. 265 
parva-infected cells. Results obtained with recombinant bovine granzyme B 266 
expressed in Cos-7 cells demonstrated many similarities to its human and murine 267 
orthologues. This included evidence that processing of the translated polypeptide is 268 
similar to that described for humans and mice, with deletion of the dipeptide/G a 269 
prerequisite for activation of cattle as well as human and murine granzyme B (21, 270 
22). Similarly, mutation of Ser195, one of the functional triad of residues at the 271 
conserved catalytic site (His, Asp and Ser), was demonstrated to ablate enzymatic 272 
activity of the active form of bovine granzyme B confirming, that as with the murine 273 
and human proteins, this residue is a critical component of the enzyme’s active site 274 
(23). These similarities extended to the substrate specificities of the human, murine 275 
and bovine forms of granzyme B, with recombinant mature bovine granzyme B 276 
showing the capacity to cleave AC-IEPD-pNA. This activity forms the basis of a 277 
sensitive and reliable in vitro method to measure murine and human granzyme B 278 
activity (24). 279 
By exploiting this cross-species similarity we were able to generate an equivalent 280 
assay for cattle and so investigate levels of biologically active bovine granzyme B 281 
and its relation to cytotoxic activity of bovine CD8+ T cells specific for T. parva-282 
infected cells, overcoming an obstacle posed by the lack of specific antibodies for 283 
bovine granzyme B. The demonstration of strong activity against this substrate 284 
 o
n
 O
ctober 18, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
 13 
confirms that cattle granzyme B displays Aspase activity, which is a characteristic 285 
feature of granzyme B, with no other known serine protease in mammals having a 286 
preference for cleaving Aspartic acid-containing substrates (25). We also 287 
demonstrated that the non-cell-permeable and cell-permeable compounds AC-IEPD-288 
CHO and Z-IETD-FMK respectively, which are known inhibitors of human and rodent 289 
granzyme B (19, 26), efficiently inhibit bovine granzyme B, further highlighting the 290 
cross-species functional similarities. However, the inability of another two inhibitors 291 
of human and murine granzyme B (Z-AAD-CMK and AC-292 
AAVALLPAVLLALLAPIETD-CHO) to block bovine granzyme B (data now shown) 293 
emphasises that extrapolating functional parameters based on orthology cannot be 294 
assumed for granzymes and must be empirically validated.  295 
This also applies to the pathways utilised by granzyme B to mediate killing, which 296 
are known to be species-dependent. Mouse granzyme B predominantly functions 297 
through the direct activation of caspases to promote apoptosis, whereas human 298 
granzyme B acts mainly via a Bid-dependent pathway (16, 27). Work described in 299 
this study demonstrates that bovine granzyme B, like its human orthologue, is 300 
capable of cleaving Bid protein in vitro, thus providing evidence indicating that Bid 301 
activation can potentially be utilised by bovine granzyme B for cell death induction. 302 
Although activation of caspases was initially thought to be important in granzyme B-303 
mediated cell death, studies by many groups revealed that requirement for caspase 304 
activation, even in mice, isn’t absolute. For example, an in vitro study of mouse 305 
CD8+ T cells showed that apoptotic nuclear damage induced by granule exocytosis 306 
was abrogated by the caspase inhibitor Z-VAD-FMK, whereas lysis of the cells was 307 
unaffected. In contrast, target cell lysis induced by the pro-apoptotic drug cisplatin 308 
was specifically blocked by this inhibitor (28). Similar results have been obtained in 309 
 o
n
 O
ctober 18, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
 14 
studies with purified human granzyme B; caspase inhibition preventing granzyme-310 
induced DNA damage but not cell lysis (29). These observations are consistent with 311 
the results obtained in this study, which showed that Z-VAD-FMK inhibited cisplatin-312 
induced apoptosis of Theileria-infected cells, but did not inhibit granzyme B-mediated 313 
cytolytic activity of cattle CD8+ T cells.  314 
T. parva has been shown to enhance the resistance of infected cells to apoptosis by 315 
utilizing NF-κB activation to induce the expression of anti-apoptotic proteins such as 316 
FLIP (which functions as a catalytically inactive form of caspase-8), X-chromosome-317 
linked inhibitor of apoptosis protein (XIAP) and c-IAP (which block caspase-9 and 318 
also downstream executioner caspases 3 and 7) (30). Studies by Guergnon and 319 
colleagues in 2003 showed that drug-induced parasite death in Theileria-infected 320 
cells resulted in apoptosis involving activation of caspases 9 and 3 and was inhibited 321 
by Z-VAD-FMK (31). These findings confirmed that bovine caspases in non-322 
granzyme B mediated killing are capable of inducing cell death and that Z-VAD-FMK 323 
is an effective inhibitor of bovine caspases.   The inhibition of killing by T. parva-324 
specific CD8+ T cell clones by Z-IETD-FMK but not Z-VAD-FMK in the current study 325 
demonstrates that T cell-mediated killing of T. parva-infected cells is dependent on 326 
granzyme B but independent of caspases. Although this may be universally 327 
applicable to bovine granzyme B mediated cytotoxicity, it is important to note that as 328 
a consequence of the negative regulation of caspases by intracellular inhibitors 329 
induced by the NF-κB pathway in T. parva-infected cells the apparent redundancy of 330 
caspases might be a feature of this specific biological context.  331 
The prime rationale for conducting this study was to better understand the molecular 332 
mechanisms that underlie the functional capacity of T. parva-specific CD8+ T-cells. 333 
The critical role that these cells play in mediating immunological protection against T. 334 
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 15 
parva (29) has led to considerable efforts to identify CD8 T cell target antigens for 335 
use in generating novel subunit vaccines (32, 33). A number of T. parva antigens 336 
recognised by CD8 T cells from immune cattle have been identified and, although 337 
they have proved to be immunogenic when used in prime-boost immunisation 338 
protocols, the CD8+ T-cells elicited generally exhibited poor cytotoxicity and were 339 
poorly protective upon in vivo parasite challenge (9). Understanding the discrepancy 340 
between immunogenicity and protective efficacy will be critical to defining ‘correlates 341 
of protection’ that can guide subsequent vaccine development. Ongoing work is 342 
applying transcriptomics to address this issue. However, such approaches used in 343 
isolation have limitations and need to be supplemented by analyses of the functional 344 
activities of the specific T cell responses, including the cytotoxic activity of CD8+ T-345 
cells. By confirming the central role of granzyme B in the cytotoxic function, this 346 
study provides the knowledge and tools that can be used to refine and enhance the 347 
immunological evaluation of T-cell responses induced in future vaccine trials. 348 
Our data, from assays of expressed biologically active granzyme B, revealed a 349 
statistically significant correlation between the levels of granzyme B enzymatic 350 
activity in cell lysates (and supernatants) of cloned CD8+ T cell lines and levels and 351 
killing of T. parva-infected cells.. Direct evidence that granzyme B is a dominant 352 
effector molecule in CD8+ T-cell mediated killing of these parasitized cells was 353 
provided by subsequent analysis showing that the membrane-permeable inhibitor of 354 
granzyme B, Z-IETD-FMK, reduced T. parva-infected cell lysis by these CD8+ T-355 
cells by 70-100%.  The highly significant association of levels of granzyme B with the 356 
cytotoxic activity of a series of cloned CD8+ T-cell lines indicates that relatively high 357 
granzyme B cell content is usually required to achieve maximal cell killing. 358 
Nevertheless, one clone (which was inhibited by the granzyme B inhibitor – clone 2 359 
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 16 
Figure 4c) consistently showed low levels of granzyme B content and release but 360 
displayed relatively strong killing (Figure 3A). The strong killing shown by this single 361 
clone despite modest granzyme B content likely reflects variation in other factors that 362 
influence cytotoxicity. This does not detract from the overall conclusion from the 363 
study that, at the polyclonal T. parva-specific CD8 + T-cell response, granzyme B is 364 
a critical mediator of cytotoxic function. There is evidence from in vitro studies in 365 
humans and mice that other granzymes, in addition to directly mediating cell death in 366 
some situations, can synergistically increase the activity of granzyme B. Examples 367 
from the literature include: i) Co-transfection of rat basophilic leukemia (RBL) cells 368 
with granzyme A and granzyme B in the presence of perforin resulting in enhanced 369 
killing of tumour targets in a synergistic manner (34); ii) human granzyme H 370 
augmentation of granzyme B-mediated killing of adenovirus-infected cells (35-37) by 371 
neutralizing the viral inhibitor of granzyme B (L4-100K assembly protein) (36, 37) 372 
and iii) human granzyme M, in addition to inducing cell death of tumor cells directly 373 
(38-40), can hydrolyse PI-9, thereby inactivating its inhibitory effect onr granzyme B 374 
(41). Thus, although our finding of strong inhibition of killing by a granzyme B 375 
inhibitor indicates that in general the roles of other granzymes do not play a 376 
prominent role in killing of T. parva-infected cells, there are clear mechanisms by 377 
which for individual T-cells complementary granzyme activities may contribute to 378 
CD8+ T killing of T. parva-infected cells. Unfortunately, further investigation of these 379 
interactions in cattle is hampered by the current lack of specific antibodies and 380 
biological assays to measure other bovine granzyme proteins.  381 
In conclusion, work described in this paper developed molecular and biochemical 382 
methods for measuringthe functional activity of bovine granzyme B, in order to 383 
determine its role in killing T. parva-infected cells by CD8+ T cells. The results 384 
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provided evidence that killing of parasitized cells occurs by granule-mediated lysis 385 
and is substantially dependent on granzyme B. However, cell killing was shown not 386 
to be caspase-dependent, and the finding that Bid is cleaved by granzyme B 387 
suggests Bid activation through cleavage is a feasible alternative/parallel killing 388 
mechanism. This study represents the first dissection of the effector mechanisms 389 
employed in killing of target cells by bovine CD8+ T cells and specifically provides 390 
the first evidence that granzyme B plays a key role in killing of T. parva-infected cells 391 
by specific CD8+ T cells.  392 
 393 
Materials and Methods 394 
Animals and T cell lines. Four Holstein-Friesian animals (011, 592, 641 and 633) 395 
homozygous for the A10 or A18 MHC I haplotypes were used for the study. Their 396 
MHC types were determined by a combination of serological typing (42) and MHC I 397 
allele-specific PCR (43). The animals were aged 18–36 month at the outset of the 398 
study and were maintained indoors on rations of hay and concentrate. Cattle were 399 
immunized against the Muguga stock of T. parva (TpM) by infection with 400 
cryopreserved sporozoites and simultaneous administration of a long-acting 401 
formulation of oxytetracycline as described previously (2). Animals were challenged 402 
with a lethal dose of sporozoites on two occasions at ~18-month intervals following 403 
immunization. All animal experiments were completed in accordance with the Animal 404 
(Scientific Procedures) Act 1986. T. parva-specific CD8+ T cell lines and clones were 405 
generated from the immune cattle and maintained as described previously (44). 406 
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Standard and semi-quantitative PCR assays. Total RNA was extracted from T. 407 
parva-specific CD8+ T cell lines from immunized cattle using Tri-reagent (Sigma) 408 
and cDNA was synthesised using the Reverse Transcription System (Promega) with 409 
priming by the Oligo (dT)15 primer, both according to the manufacturer’s 410 
instructions. The primers for granzymes and perforin and the protocols for standard 411 
PCR reactions were as previously described (12). For semi-quantitative PCR, the 412 
sequences of primers were as follows: granzyme B: 5’-ACT GGA ATC AGG ATG 413 
TCC AGA G-3’ (Forward), 5’- TTT GGG TCC CCC ACA CAC AG-3’ (Reverse) and 414 
Gapdh: 5’-ACC CCT TCA TTG ACC TTC AC-3’ (Forward); 5’-TTC ACG CCC ATC 415 
ACA AAC ATG-3’ (Reverse). The PCR reactions were composed of 20pmol of 416 
granzyme B/perforin primers and 10pmol of Gapdh primers, 2.5 units BIOTAQ (5 417 
units/ul, Bioline), 2.5ul SM-0005 buffer, 0.05ug of cDNA template and nuclease-free 418 
water to give a final volume of 25ul. The primers for perforin and the protocol for 419 
PCR programme were as described above. Semi-quantified PCR products were 420 
analysed by 1.5% agarose gel electrophoresis and the density of the specific bands 421 
was measured by computer software (KODAK 1D 3.6 version). 422 
Cloning of bovine granzyme B cDNA constructs. Full-length bovine wild-type 423 
(WT) granzyme B was amplified from cDNA by high fidelity PCR, using primers 424 
flanking the coding sequence as previously described (12). The high fidelity PCR 425 
protocol was composed of 10pmol of primers, 1.2 unit Pfu DNA polymerase (3 426 
units/ul, Promega), 10x Buffer with MgSO4 (Promega), 10mM dNTP, 0.5ug of cDNA 427 
template and nuclease-free water to give a final volume of 50ul. The programme 428 
used was as follows: 95°C for 2 min, 30 cycles of 95°C for 1min followed by 55°C for 429 
0.5 min and 72°C for 2.5 min, and a final extension period of 72°C for 5 min. To 430 
generate cDNA encoding active granzyme B, six nucleotides encoding a dipeptide 431 
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segment in the wild-type granzyme B cDNA (which inhibits granzyme B function and 432 
is present in pro-granzyme B but absent in fully mature granzyme B) were deleted by 433 
PCR splice overlap extension (PCR-SOE), based on procedures described for 434 
human granzyme B (21). Briefly, two PCR assays were initially performed to 435 
generate two overlapping fragments that carry the six-nucleotide deletion in the 436 
overlapping segment. These reactions utilised the external flanking primers 437 
described above with the following internal primers: 5’- 438 
CAAAGGCAATCATCGGGGGCCATG-3’ (Forward); 5’- 439 
CCCGATGATTGCCTTTGCCCTGGG-3’ (Reverse). The resulting two fragments 440 
were mixed, denatured and annealed to produce deletion mutant DNA templates and 441 
amplification of the extended DNAs was performed with flanking primers in a further 442 
PCR. Substitution of Ser with Ala at the active site of dipeptide-knockout cDNA was 443 
performed by ‘megaprimer’ PCR mutagenesis (45, 46) using an internal mutagenic 444 
forward primer incorporating the mutation as follows: 5’-445 
AGAAAGCTTCCTTTCAGGGGGACGCGG-3’. Briefly, an initial 5 cycles of a PCR 446 
reaction containing 50pmol of internal mutagenic forward primer and 2.5pmol of a 447 
flanking reverse primer (as described above) was followed by a prolonged extension 448 
step to generate mutant mega fragments. 50pmol of the other flanking primer (as 449 
described above) was added to the mutant templates and the PCR reaction 450 
subjected to a further 25 cycles to generate full-length product containing the 451 
mutation. All three bovine granzmye B cDNAs were sub-cloned into the pFLAG-452 
CMVtm-5a expression vector (Sigma) and nucleotide sequencing performed by DBS 453 
Genomic (Durham University). 454 
Expression of granzyme B in Cos-7 cells. Cos-7 cells were maintained in 455 
Dulbecco’s Minimal Essential Medium (DMEM, Invitrogen) supplemented with 10% 456 
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FCS, 5x10-5 M 2-Mercaptoethanol, 4mM glutamine, 100U/ml penicillin and 100ug/ml 457 
streptomycin, at 37°C with 5% CO2. Cos-7 cells were transfected in 75cm
2 flasks 458 
with the pFLAG-CMVtm-5a vector containing each of the three cattle granzyme B 459 
recombinant cDNAs (wild type (60ug), dipeptide knockout (60ug) and knockout with 460 
a Ser195Ala substitution (40ug)) or vector only (60ug). The transient transfection 461 
was performed by using the Lipofectaminetm 2000 reagent (Invitrogen) according to 462 
the manufacturer’s protocol. Transfected cells were harvested after 48h, washed and 463 
suspended in cold PBS and analysed in further experiments. To test for expression 464 
of transfected DNA products, cytospin smears of cells were examined 465 
microscopically with anti-FLAG M2 antibody (1:500 dilution; IgG1; Sigma). The 466 
transfection efficiency of pFLAG vectors containing three bovine granzyme B 467 
recombinant cDNAs containing WT, the dipeptide knockout and the knockout with an 468 
additional Ser195Ala substitution was 35%, 33% and 33%, respectively.  469 
Granzyme B protease activity in transfected Cos-7 cells. Cell lysis and assay of 470 
protease activity were performed as previously described for equine granzyme B 471 
(47). Briefly, aliquots of 1ml of PBS-washed Cos-7 cells adjusted to 2x106 cells/ml in 472 
PBS were pelleted and lysed by addition of 0.2ml lysis buffer (1%Triton X-100, 473 
50mM Tris, pH8.0 and 2ul of Benzonase Nuclease 25U/ml, Purity>99%, Merck). 474 
Following incubation on ice for 20min, lysed cells were centrifuged at 21,000 x g for 475 
10min at 0°C to pellet cell nuclei and other cell debris. Supernatants were harvested 476 
and assayed in duplicate for protease activity; aliquots of 25ul of lysis supernatant, 477 
granzyme B substrate Ac-IEPD-pNA, (Calbiochem) at a final concentration of 300uM 478 
and reaction buffer (0.1M Hepes, pH 7.0; 0.3M NaCl; 1mM EDTA) in a total volume 479 
of 250ul/well were added into the wells of Falcon™ 96-Well Flat bottomed 480 
Microplates (BD). The chymotrypsin substrate I, Suc-GGF-pNA (Calbiochem), was 481 
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used as a negative control for substrate specificity. The reaction was composed of 482 
25ul of lysis supernatant, 1mM Suc-GGF-pNA in the final concentration and the 483 
reaction buffer (50mM Tris, 100mM NaCl, pH8.0) in a total volume of 125ul. Mixtures 484 
were incubated at 37°C for 4h and the colour reaction generated by cleavage of the 485 
pNA substrate measured at a wavelength of 405nm by using a Synergy™ HT Multi-486 
Mode Microplate Reader (BioTek). For inhibition of active bovine granzyme B 487 
protease activity in lysates, aliquots of 25ul of lysis supernatant containing active 488 
bovine granzyme B were pre-incubated with 10uM Ac-IEPD-CHO (the granzyme B 489 
inhibitor, Calbiochem) at 37°C for 0.5h. 490 
Granzyme B activity in CD8+ T cell lines. Methods used for measurement of 491 
granzyme B in T cell lysates and supernatants were based on procedures previously 492 
described for human and equine granzyme B (24, 47). CD8+ T cells washed in PBS 493 
were adjusted to 1x106 cells/ml in PBS, pelleted and lysed by addition of 50ul of a 494 
lysis buffer per ml as described above. To examine granzyme B release, aliquots of 495 
1x106 CD8+ T cells were distributed into the wells of 96-well V-bottomed plates 496 
together with 5x105 target cells in a total volume of 200ul phenol-red-free complete 497 
media (RPMI 1640 with 5% FCS, Invitrogen,). Control wells containing effector cells 498 
and medium were also included. After incubation in an atmosphere of 5% CO2 at 499 
37°C for 4h, the plates were centrifuging for 10min at 400xg and supernatants were 500 
collected. Granzyme B activity was measured by adding aliquots of 10ul of cell 501 
lysates or 40ul of culture supernatants in duplicate to wells of Falcon™ 96-well flat-502 
bottomed Microplates (BD) together with 200uM granzyme B substrate, Ac-IEPD-503 
pNA, (Calbiochem) and reaction buffer (0.1M HEPES, pH7.0; 0.3M NaCl; 1mM 504 
EDTA) in a total volume of 100ul/well. Wells containing reaction buffer and substrate 505 
control were also included as controls. Mixtures were incubated at 37°C for 4h and 506 
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the colour reaction generated by cleavage of the pNA (p-nitroaniline) substrate 507 
measured at a wavelength of 405nm using a Synergy™ HT Multi-Mode Microplate 508 
Reader (BioTek). To test for specificity of the reaction, CD8+ T cells were pre-509 
incubated with the cell-permeable granzyme B inhibitor, Z-IETD-FMK (40uM) for 1h 510 
prior to preparation and testing of cell lysates as describe above. 40uM Z-VAD-FMK, 511 
a pan-caspase inhibitor was used as a negative control, whereas a non-cell-512 
permeable granzyme B inhibitor, AC-IEPD-CHO (10uM) was used to inhibit 513 
granzyme B activity in lysates as a positive control.  514 
Cytotoxicity assays. Standard 4-hour [111In]-release cytotoxicity assays were used 515 
to measure cytotoxicity of CD8+ T cell clones, using as target cells either autologous 516 
T. parva-infected cells or autologous T. annulata - transformed cells incubated with 517 
peptide for 0.5h prior to the assay (44). Peptides were supplied by Pepscan Systems 518 
(Lelystad, The Netherlands). All assays were conducted in duplicate, and controls 519 
included T. annulata-infected target cells without added peptide and, where 520 
appropriate, MHC-mismatched T. parva-infected target cells. Cytotoxicity assays 521 
were established and specific lysis was measured as described previously (44). For 522 
inhibition of perforin activity, effector cells were pre-incubated with ten-fold dilutions 523 
of concanamycin A (CMA) at final concentrations ranging from 0.1ug/ml to 524 
1000ug/ml for 2h at 37 °C. For inhibition of granzyme B activity, effector cells were 525 
pre-incubated for 1h at 37°C with 40uM Z-IETD-FMK and the negative control, pan-526 
caspase inhibitor Z-VAD-FMK (40uM). For inhibition of caspase activity, 111In 527 
labelled target cells were pre-incubated with 80uM Z-VAD-FMK and the negative 528 
control, cathepsin B Inhibitor Z-FA-FMK (80uM) for 1h at 37°C. 529 
Generation of recombinant bovine Bid. Wild-type bovine Bid cDNA was amplified 530 
using primers flanking the full-length coding region of bovine Bid as follows: 5’-531 
 o
n
 O
ctober 18, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
 23 
TAGCATATGGATTTGAAGGTTA-3’ (Forward); 5’-532 
TGCTGGATCCGAGTGGTCACTCAGTCCAT-3’ (Reverse). The amplified PCR 533 
products were purified and sub-cloned into the NdeI and BamHI sides of pET-15b 534 
vector (Novagen) and nucleotide sequencing performed by DBS Genomic (Durham 535 
University). The protocols for expression and purification of recombinant bovine Bid 536 
proteins were performed as previously described for human Bid (48). Briefly, pET-537 
15b expression vectors containing wild-type bovine Bid cDNA were transformed in 538 
E.coli BL21 (DE3) pLYsS (Novagen) and expressed in the presence of IPTG. The 539 
expressed products, which carry an N-terminal His-Tag sequence, were purified with 540 
automated immobilised metal affinity chromatography (IMAC) using a nickel affinity 541 
column (Qiagen) and further purified with automated ion exchange chromatography 542 
(IEC) using a Mono Q column (Pharmacia).  543 
Proteolysis of recombinant bovine Bid by bovine granzyme B. Two-fold dilutions 544 
of lysates containing active bovine granzyme B at final concentrations ranging from 545 
10ng to 0.04ng in 10ul reaction volumes were incubated with 3ug of recombinant 546 
bovine Bid for 2h at 37°C. Inactive mutated bovine granzyme B (an alanine 547 
substitution at position 195), mock (pFLAG without an insert) and Cos-7 cells alone 548 
were used as negative controls for granzyme B proteolysis specificity. Reaction 549 
products were separated by SDS-PAGE (NuPAGE 4-12% Bis-Tris gel, Thermo 550 
Fisher) and visualized by Coomassie blue staining. The reaction products were 551 
transferred using the iBlot (Thermo Fisher) for Western blotting, according to the 552 
manufacturer’s instructions. The blots were probed with anti-His Tag antibody 553 
(1:2500 dilution, Thermo Fisher) and anti-FLAG M2 antibody (1:1000 dilution, Sigma) 554 
and detected by chemiluminescence using HRP-labelled rabbit anti-mouse IgG 555 
(H+L) secondary antibody (1:5000 dilution, Thermo Fisher). 556 
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Statistical analysis. Statistical analyses were performed using Minitab software 557 
(Minitab® 15.1.20.0, Minitab Inc.). The correlation between variables was analysed 558 
by Pearson’s correlation test. P-values < 0.05 were considered significant. 559 
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Figure 1. (A). Amino acid sequences from nucleotide sequences of three 732 
recombinant forms of bovine granzyme B cDNA, aligned with the reference 733 
sequence from the genome database. Granzyme B - CDs - the full length cDNA from 734 
bovine genome (corr_ENSBTAG00000010057); Granzyme B - WT - pFLAG-CMVtm-735 
5a vector containing wide type granzyme B; Granzyme B - Function - pFLAG-736 
CMVtm-5a vector containing functional granzyme B; Granzyme B - Mutant - pFLAG-737 
CMVtm-5a vector containing functional granzyme B with Ser195 to Ala195 mutation. 738 
Dot-Identical; Dash-Gap; Leader peptide is highlighted in a red box; Dipeptide/GE is 739 
in a yellow box; Ser195Ala is in a black box; FLAG epitope-tag sequence of the 740 
pFLAG-CMVtm-5a vector is in blue. (B). Enzymatic activity of different recombinant 741 
forms of bovine granzyme B tested on a granzyme B-specific substrate AC-IEPD-742 
pNA (Filled bars) and a control substrate Suc-GGF-pNA (Empty bars): Cos-7 cells 743 
were transiently transfected with unmodified granzyme B cDNA (WT), cDNA with the 744 
GE dipeptide deleted (Function) or cDNA containing a deletion of the dipeptide and 745 
an alanine substitution at position 195 (Mutant). The transfection efficiency of Cos-7 746 
cells with three granzyme B constructs was 35%, 33% and 33%, respectively. 747 
Lysates of the transfected cells collected after 48 hours were incubated with the 748 
substrates for 4 hours. Controls consisted of lysates of cells transfected with pFLAG 749 
without an insert (Mock) and buffer (No cells) added to the substrate. Colour reaction 750 
generated after 4 hours by cleavage of the pNA substrate were measured at a 751 
wavelength of 405nm using a Synergy™ HT Multi-Mode Microplate Reader (BioTek). 752 
(C). Inhibition of the functional recombinant cattle granzyme B by preincubating with 753 
10uM granzyme B specific inhibitor AC-IEPD-CHO for 0.5h.  754 
 755 
 756 
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Figure 2. (A). PCR products obtained for each of the bovine granule enzymes from 757 
an uncloned T. parva-specific CD8+ T cell line (641). The sizes of the PCR products 758 
obtained were: granzyme A (A) - 838bp; granzyme O (O) - 849bp; granzyme B (B) - 759 
818bp; granzyme H (H) - 820bp; granzyme K (K) - 889bp; granzyme M (M) - 833bp; 760 
Perforin (PFN) - 1275bp; Negative controls (primers with no added cDNA template) 761 
were included in the left of the panel. (B). Agarose gels showing the PCR products 762 
for granzyme B (457bp), perforin (1275bp) and the GAPDH control (304bp). Days 763 
after antigenic stimulation are shown. (C). Changes in quantity of PCR product 764 
(vertical axis) at different times following antigenic stimulation, normalised in relation 765 
to that of the GAPDH product obtained from the same sample. (D). Cytotoxic activity 766 
of 8 T. parva-specific CD8+ T cell clones from two different animals (641 and 1011) 767 
assayed on autologous T. parva-infected targets. (E). Agarose gels showing the 768 
PCR products for granzyme B (457bp), perforin (1275bp) and the GAPDH control 769 
(304bp) from 8 T. parva-specific CD8+ T cell clones (D). (F). Correlation of killing of 770 
Theileria-infected target cells by CD8+ T cell clones with levels of mRNA expression 771 
of granzyme B (r= 0.438, p= 0.278) and perforin (r= -0.104, p= 0.806). Changes in 772 
quantity of PCR product (vertical axis) in different T cell clones, normalised in 773 
relation to that of the GAPDH product obtained from the same sample. (B, E) A 774 
negative control (-), without added template, and a positive control (+), consisting of 775 
primers with cDNA template of an uncloned T. parva-specific CD8+ T cell line (641) 776 
day 7 after 3rd stimulation are included. The density of the all PCR amplicon bands 777 
was measured by Kodak 1D software (version 3.6). The correlation between 778 
variables was analysed by Pearson’s correlation test. P-values < 0.05 were 779 
considered significant. 780 
 781 
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 782 
Figure 3. (A). Cytotoxic activity and levels of granzyme B content and release of 12 783 
T. parva-specific CD8+ T cell clones isolated from two animals (641 and 633) were 784 
assayed with autologous T. parva-infected cell target cells. A standard effector to 785 
target ratio of 2:1 was used. Correlation of granzyme B cellular activity with (B) levels 786 
of released granzyme B following antigenic stimulation (r =0.953, p <0.0001) and, 787 
(C) levels of killing of Theileria-infected target cells by CD8+ T cell clones (r =0.732, 788 
p =0.007). The correlation between variables was analysed by Pearson’s correlation 789 
test. P-values < 0.05 were considered significant. 790 
  791 
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Figure 4. Inhibition of the cytotoxic activity of (A) an un-cloned (‘bulk’) CD8+ T cell 792 
line from animal 011 and (B) three CD8+ T cell lines from animal 592 by incubation 793 
with the perforin inhibitor concanavalin A (CMA), and (C) three CD8+ T cell lines 794 
from animal 641 by incubation with the granzyme B inhibitor Z-IETD-FMK. (A, B) 795 
Effectors (1x104) were pre-incubated with various concentrations of CMA for 2h and 796 
tested in a 4-h cytotoxicity assay with [111In]-labelled autologous TpM target cells and 797 
MHC-matched target cells pulsed with Tp249-59 peptide (1000ng/ml). (C) Three 798 
cloned CD8+ T cell lines (1x104) were pre-incubated for 1 h with 40uM Z-IETD-FMK 799 
and a negative control, Z-VAD-FMK. Labelled target cells alone were also incubated 800 
with the inhibitors in the assay. A standard effector to target ratio of 2:1 was used. 801 
 802 
  803 
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Figure 5. (A). 111In-labelled peptide-pulsed target cells (MHC-matched target cells, 804 
5x103 + Tp1214-224, 100ng/ml) were pre-incubated with the ‘pan-caspase’ inhibitor Z-805 
VAD-FMK (80uM) for 1h and tested in a 4-hour cytotoxicity assay with two Tp1-806 
specific cloned CD8+ T cell lines from animal 641. As controls, effector cells (1x104) 807 
pre-incubated with the ‘perforin’ inhibitor CMA (10ng/ml) for 2h or the ‘granzyme B’ 808 
inhibitor Z-IETD-FMK (40uM) for 1h were tested in the same experiment. Labelled 809 
target cell alone were also incubated with these inhibitors in the assay. A standard 810 
effector to target ratio of 2:1 was used. (B). Expression vector pET-15b, carrying an 811 
N-terminal His-Tag sequence followed by full-length coding sequence of bovine Bid 812 
was expressed in E. coli BL21 (DE3) in the presence (+) or absence (-) of IPTG and 813 
the expressed products were purified using automated immobilised metal affinity 814 
chromatography (IMAC) and automated ion exchange chromatography (IEC). 815 
Products were separated by SDS-PAGE and visualized by Commassie blue staining. 816 
The predicted size of bovine recombinant Bid is 23.7 kD. (C, D) Purified recombinant 817 
bovine Bid proteins (3ug) were incubated with indicated concentrations of active 818 
bovine granzyme B for 2 h at 37oC. The reaction products were separated by SDS-819 
PAGE and visualized by Commassie blue staining (C) and full-length recombinant 820 
Bid and truncated Bid (N-terminus) were detected by anti-His-Tag antibody and 821 
recombinant granzyme B was detected by anti-FLAG M2 antibody in Western Blot 822 
(D). (C, D) Inactive bovine granzyme B mutant (an alanine substitution at position 823 
195), mock (pFLAG without an insert) and Cos-7 cells alone were included as 824 
negative controls for granzyme B proteolysis specificity  825 
 826 
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